key: cord-0963000-buc0hun6
authors: Pagnesi, Matteo; Adamo, Marianna; Metra, Marco
title: March 2021 at a glance: focus on epidemiology, prevention and COVID‐19
date: 2021-04-29
journal: Eur J Heart Fail
DOI: 10.1002/ejhf.1878
sha: e505176b2338b779bef2ce7fc233794090e8f482
doc_id: 963000
cord_uid: buc0hun6

nan

This issue hosts a landmark paper with the universal definition of heart failure (HF) developed by the HF Association (HFA), the HF Society of America and the Japanese HF Society and endorsed by four other HF societies. 1 HF is defined as 'a clinical syndrome with symptoms and/or signs caused by a structural and/or functional cardiac abnormality and corroborated by elevated natriuretic peptide levels and/or objective evidence of pulmonary or systemic congestion.' Four stages are described: Stage A, for patients at risk for HF but without evidence of heart disease; Stage B, pre-HF, for patients without current or prior symptoms or signs of HF but with evidence of structural heart disease or abnormal cardiac function, or elevated natriuretic peptide levels; Stage C, HF, for patients with current or prior symptoms and/or signs of HF caused by a structural and/or functional cardiac abnormality; Stage D, advanced HF, for patients with severe symptoms and/or signs of HF at rest, recurrent hospitalizations despite guideline-directed medical therapy (GDMT), refractory or intolerant to GDMT, and requiring advanced therapies such as transplant, mechanical circulatory support, or palliative care. 1 Stage D overlaps with advanced HF, as previously defined by a HFA position statement. 2 A classification of HF according to left ventricular ejection fraction (EF) is also adopted with patients classified into those with reduced EF (HFrEF, EF ≤40%), mildly reduced EF (HFmrEF, EF 41-49%), preserved EF (HFpEF, EF ≥50%) and improved EF (HFimpEF, baseline EF ≤40%, a ≥10 point increase in EF and a second EF >40%). 1 Attended by an outstanding editorial comments by Dr. Braunwald, 3 and in line with recent consensus recommendations on definitions for the assessment of HF therapies, 4 the universal definition of HF represents a fundamental framework to standardize the identification and classification of patients with HF both for daily practice and clinical studies.

A substudy of SPRINT confirmed the role of kidney function and albuminuria for the prediction of HF events in hypertensive subjects. In addition, these variables did not influence the effects of intensive blood pressure control (target systolic blood pressure .

<120 mmHg), compared to standard treatment, for the reduction of HF risk. 5 In PREVEND, enrolling 8202 individuals with a mean follow-up of 11.3 ± 3.1 years, N-terminal pro-B-type natriuretic peptide (NT-proBNP), mid-regional pro-A-type natriuretic peptide (MR-proANP) and cardiac troponin T (cTnT) were associated with incident HF, and combined NT-proBNP and cTnT measurements improved HF risk prediction in overweight and obese subjects (both P < 0.001). 6 These findings reinforce available evidence on the role of NT-proBNP, and/or the NT-proBNP and troponin combination, for the prediction of incident HF. [7] [8] [9] Epidemiology Changes in the epidemiology and characteristics of cardiogenic shock and acute HF have occurred in the last years. 10 

Left ventricular EF remains the most important measurement to classify patients with HF. 1 In a cohort study on 499 153 patients in Australia, Stewart et al. 14 identified sex-based differences in the risk of mortality associated with a left ventricular EF <65.0-69.9%, nadir of mortality in both sexes, with a greater risk at higher left ventricular EF values in women, compared with men. Advanced age is associated with a decline in GDMT use and higher mortality in patients with HF. 15 In an analysis of BIOSTAT-CHF, Mordi et al. 16 demonstrated that achieving higher doses of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) was associated with lower mortality or HF hospitalizations regardless of age, whereas achieving higher doses of β-blockers was associated with improved outcome only in younger patients (interaction P = 0.034). These findings could be helpful to refine ACEi/ARB and β-blocker up-titration in patients with HF. 17 

In line with available evidence showing worse clinical outcomes in COVID-19 patients with concomitant HF, [18] [19] [20] [21] [22] an analysis of a Spanish cohort showed that NT-proBNP is frequently elevated in COVID-19 and independently associated with mortality (adjusted hazard ratio per logarithmic unit 1.28, 95% CI 1.13-1.44, P < 0.001). 23 Cardiopulmonary and haemodynamic abnormalities characterize critically ill COVID-19 patients. 18, 24 Of note, these patients showed a typical and rather specific inflammatory and cardiac myocyte-related microRNA up-regulation. 25 Consistent with published data showing the lack of increased COVID-19 severity in patients treated with ACEi or ARBs despite increased ACE2 expression, 19, 26, 27 an analysis on 1.4 million patients from the Swedish National Patient Registry did not find an association between the use of ACEi/ARBs or mineralocorticoid receptor antagonists and an increased risk of hospitalization for or death from COVID- 19. 28 

Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association

Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology

The path to universality

Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium

Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy

Relationship between body mass index, cardiovascular biomarkers and incident heart failure

Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations

Prediction of incident heart failure by serum amino-terminal pro-B-type natriuretic peptide level in a community-based cohort

Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis

Epidemiology, pathophysiology and contemporary management of cardiogenic shock -a position statement from the Heart Failure Association of the European Society of Cardiology

Temporal trends in incidence and patient characteristics in cardiogenic shock following acute myocardial infarction from 2010 to 2017: a Danish cohort study

Trends in cardiogenic shock complicating acute myocardial infarction

Frequency, trends and institutional variation in 30-day all-cause mortality and unplanned readmissions following hospitalisation for heart failure in Australia and New Zealand

Ejection fraction and mortality: a nationwide register-based cohort study of 499 153 women and men

European Society of Cardiology Heart Failure Long-Term Registry Investigators Group. Sex-and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry

Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF

Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries

Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology

COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease

Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications

The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic

Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study

Characterization of NT-proBNP in a large cohort of COVID-19 patients

Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization

Circulating cardiovascular microRNAs in critically ill COVID-19 patients

Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust

Association between reninangiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis